Jacobio Pharmaceuticals Group Co., Ltd. (SEHK: 1167)
Health Care · Biotechnology · CN
HK$5.57
-7.40% today · -29.2% 1Y
Jacobio Pharmaceuticals Group Co., Ltd. (SEHK: 1167) operates in the Biotechnology industry within the Health Care sector. The company is valued at $555.24M and employs 207 people.
Over the last twelve months the share price has lost 29.2%, trading between 3.98 and 9.29.
Tweenvest scores Jacobio Pharmaceuticals Group Co., Ltd. across four factors: quality 41/100, value 47/100, growth 0/100. Its strongest factor is value.
1167 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $555.24M
- Revenue (TTM)
- $108.75M
- P/E
- 7.27
- EPS
- 0.66
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- HK$9.29
- 52-week low
- HK$3.98
- Avg volume (3M)
- —
- Shares outstanding
- 782.28M
- Employees
- 207
- Next earnings
- —
About Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
- ISIN
- KYG4987A1094
- Founded
- 2015
- Listed since
- Dec 21, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Serum Bio-Technology Co., Ltd.SHSE: 688163 | $563.39M | CN¥34.87 | -12.83% |
| Shanghai MicuRx Pharmaceutical Co., Ltd.SHSE: 688373 | $561.38M | CN¥5.73 | -0.87% |
| Zhejiang Orient Gene Biotech Co., LtdSHSE: 688298 | $557.20M | CN¥19.50 | +0.67% |
| DBV Technologies S.A.ENXTPA: DBV | $555.98M | €1.68 | -11.87% |
| Jiangsu Sihuan Bioengineering Co., LtdSZSE: 000518 | $553.35M | CN¥3.60 | +0.28% |
| Thalys Medical Technology Group CorporationSHSE: 603716 | $545.42M | CN¥16.47 | -0.90% |
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $541.29M | HK$10.43 | -2.71% |
| Valneva SEENXTPA: VLA | $537.87M | €2.53 | +0.08% |
Figures last refreshed Oct 11, 2026.